# Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

> **NCT00415571** · PHASE2 · COMPLETED · sponsor: **QuatRx Pharmaceuticals Company** · enrollment: 72 (estimated)

## Conditions studied

- Hypogonadism
- Erectile Dysfunction

## Interventions

- **DRUG:** Fispemifene (once daily for 8 weeks)

## Key facts

- **NCT ID:** NCT00415571
- **Lead sponsor:** QuatRx Pharmaceuticals Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** 2008-08
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2010-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415571, "Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00415571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*